MGMathilde Gay-Bellile

Mathilde Gay-Bellile

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mathilde Gay-Bellile has a total of 115 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Etude de l'instabilité génomique et du statut des télomères dans le cancer du sein.

    by Mathilde Gay-Bellile

    Dans le cancer du sein, la recherche de nouveaux biomarqueurs, permettant de prédire la réponse thérapeutique et de déterminer le pronostic d’une patiente, est importante pour adapter au mieux les traitements mais aussi pour améliorer la compréhension des phénomènes physiopathologiques. Nous nous sommes particulièrement intéressés aux cancers du sein traités par chimiothérapie néoadjuvante. Nous avons étudié, dans des biopsies tumorales réalisées avant traitement et dans des résidus tumoraux, à la fois les paramètres télomériques et la réparation des lésions d’ADN puisque ces 2 mécanismes, lorsqu’ils sont dysfonctionnels, sont à l’origine d’une forte instabilité génomique. Nous avons corrélés ces paramètres à la réponse à la chimiothérapie néoadjuvante et à la survie des patientes. Dans un 1er temps, nous avons montré que des télomères courts, une surexpression de la télomérase (TERT) et une sous-expression d’une protéine impliquée dans différents mécanismes de réparation de l’ADN, ERCC1, sont des marqueurs de mauvais pronostic. La dysfonction simultanée des télomères et des mécanismes de réparation de l’ADN peut contribuer de façon synergique à la progression tumorale et à la résistance thérapeutique. Nous avons ensuite étudié une population de tumeurs du sein triple négatives. Nous avons montré que des télomères courts sont associés aux tumeurs les plus agressives et les plus résistantes. De plus, une résistance thérapeutique est retrouvée associée à une instabilité génomique plus importante. Nous avons enfin analysé les altérations génomiques caractéristiques permettant d’identifier le statut BRCA1-like. Le profil BRCA1-like est corrélé à une résistance thérapeutique et à une forte instabilité génomique.Enfin, nous avons réalisé une étude plus fondamentale visant à identifier les mécanismes à l’origine de la réactivation de la télomérase dans le cancer du sein. Nous avons démontré que la surexpression de TERT, dans le cancer du sein, n’est pas liée à la présence de mutations somatiques activatrices mais plutôt à celle de gain du locus TERT. Ces gains sont associés à une résistance thérapeutique et un risque de rechute plus important. Enfin, la présence de gain de TERT combinée à la surexpression de MYC, permet de définir un sous groupe de très mauvais pronostique et pourrait être utilisé pour évaluer le risque de récidives. Les paramètres télomériques et l’instabilité génomique semblent donc être des biomarqueurs prédictifs de la réponse à la chimiothérapie néoadjuvante dans le cancer du sein triple négatif. Ces paramètres ont également une forte valeur pronostique dans le cancer du sein en général et pourraient être utilisés cliniquement comme biomarqueurs utiles au choix des traitements.

  • Open Access

    Detection Rate and Spectrum of Pathogenic Variations in a Cohort of 83 Patients with Suspected Hereditary Risk of Kidney Cancer

    by Zangbéwendé Guy Ouedraogo, Florian Ceruti, Mathis Lepage, Mathilde Gay-Bellile, Nancy Uhrhammer, Flora Ponelle-Chachuat, Yannick Bidet, Maud Privat, Mathias Cavaillé

    Hereditary predisposition to cancer affects about 3–5% of renal cancers. Testing criteria have been proposed in France for genetic testing of non-syndromic renal cancer. Our study explores the detection rates associated with our testing criteria. Using a comprehensive gene panel including 8 genes related to renal cancer and 50 genes related to hereditary predisposition to other cancers, we evaluated the detection rate of pathogenic variants in a cohort of 83 patients with suspected renal cancer predisposition. The detection rate was 7.2% for the renal cancer genes, which was 2.41-fold higher than the estimated 3% proportion of unselected kidney cases with inherited risk. Pathogenic variants in renal cancer genes were observed in 44.5% of syndromic cases, and in 2.7% of non-syndromic cases. Incidental findings were observed in CHEK2, MSH2, MUTYH and WRN. CHEK2 was associated with renal cancer (OR at 7.14; 95% CI 1.74–29.6; p < 0.003) in our study in comparison to the gnomAD control population. The detection rate in renal cancer genes was low in non-syndromic cases. Additional causal mechanisms are probably involved, and further research is required to find them. A study of the management of renal cancer risk for CHEK2 pathogenic variant carriers is needed.


  • Open Access

    Case Series of 11 CDH1 Families (47 Carriers) Including Incidental Findings, Signet Ring Cell Colon Cancer and Review of the Literature

    by Mathis Lepage, Nancy Uhrhammer, Maud Privat, Flora Ponelle-Chachuat, Myriam Kossai, Julien Scanzi, Zangbéwendé Guy Ouedraogo, Mathilde Gay-Bellile, Yannick Bidet, Mathias Cavaillé

    Germline pathogenic variants in E-cadherin (CDH1) confer high risk of developing lobular breast cancer and diffuse gastric cancer (DGC). The cumulative risk of DGC in CDH1 carriers has been recently reassessed (from 40–83% by age 80 to 25–42%) and varies according to the presence and number of gastric cancers in the family. As there is no accurate estimate of the risk of gastric cancer in families without DGC, the International Gastric Cancer Linkage Consortium recommendation is not straightforward: prophylactic gastrectomy or endoscopic surveillance should be proposed for these families. The inclusion of CDH1 in constitutional gene panels for hereditary breast and ovarian cancer and for gastrointestinal cancers, recommended by the French Genetic and Cancer Consortium in 2018 and 2020, leads to the identification of families with lobular cancer without DGC but also to incidental findings of pathogenic variants. Management of CDH1 carriers in case of incidental findings is complex and causes dilemmas for both patients and providers. We report eleven families (47 CDH1 carriers) from our oncogenetic department specialized in breast and ovarian cancer, including four incidental findings. We confirmed that six families did not have diffuse gastric cancer in their medical records. We discuss the management of the risk of diffuse gastric cancer in Hereditary Lobular Breast Cancer (HLBC) through a family of 11 CDH1 carriers where foci were identified in endoscopic surveillance. We also report a new colon signet ring cancer case in a CDH1 carrier, a rare aggressive cancer included in CDH1-related malignancies.


  • Open Access

    Analysis of 11 candidate genes in 849 adult patients with suspected hereditary cancer predisposition

    by Mathias Cavaillé, Nancy Uhrhammer, Maud Privat, Flora Ponelle‐Chachuat, Mathilde Gay‐Bellile, Mathis Lepage, Ioana Molnar, Sandrine Viala, Yannick Bidet, Yves‐Jean Bignon

    Hereditary predisposition to cancer concerns between 5% and 10% of cancers. The main genes involved in the most frequent syndromes (hereditary breast and ovarian cancer syndrome, hereditary nonpolyposis colorectal cancer syndrome) were identified in the 1990s. Exploration of their functional pathways then identified novel genes for hereditary predisposition to cancer, and candidate genes whose involvement remains unclear. To determine the contribution of truncating variants in 11 candidate genes (BARD1, FAM175A, FANCM, MLH3, MRE11A, PMS1, RAD50, RAD51, RAD51B, RINT1, and XRCC2) to cancer predisposition in a population of interest, panel sequencing was performed in 849 patients with a suspected hereditary predisposition to cancer for whom a diagnostic panel of 38 genes identified no causal mutation. Sixteen truncating variants were found in FANCM (n = 7), RINT1 (n = 4), RAD50 (n = 2), BARD1, PMS1, and RAD51B. FANCM (adjusted P‐value: .03) and RINT1 (adjusted P‐value: .04) were significantly associated with hereditary breast and ovarian cancer. However, further studies are required to determinate the risk of cancer, including the segregation of the variants in the families of our cases. No mutation was identified in RAD51, MRE11A, FAM175A, XRCC2, or MLH3. The involvement of these genes in the hereditary predisposition to cancer cannot be ruled out, although if it exists it is rare or does not seem to involve truncating variants.


  • Open Access

    Feedback of extended panel sequencing in 1530 patients referred for suspicion of hereditary predisposition to adult cancers

    by Mathias Cavaillé, Nancy Uhrhammer, Maud Privat, Flora Ponelle‐Chachuat, Mathilde Gay‐Bellile, Mathis Lepage, Sandrine Viala, Yannick Bidet, Yves‐Jean Bignon

    High‐throughput sequencing analysis represented both a medical diagnosis and technological revolution. Gene panel analysis is now routinely performed in the exploration of hereditary predisposition to cancer, which is becoming increasingly heterogeneous, both clinically and molecularly. We present 1530 patients with suspicion of hereditary predisposition to cancer, for which two types of analyses were performed: a) oriented according to the clinical presentation (n = 417), or b) extended to genes involved in hereditary predisposition to adult cancer (n = 1113). Extended panel analysis had a higher detection rate compared to oriented analysis in hereditary predisposition to breast / ovarian cancer (P < .001) and in digestive cancers (P < .094) (respectively 15% vs 5% and 19.3%, vs 12.5%). This higher detection is explained by the inclusion of moderate penetrance genes, as well as the identification of incident mutations and double mutations. Our study underscores the utility of proposing extended gene panel analysis to patients with suspicion of hereditary predisposition to adult cancer.


  • Open Access

    Is BRCA2 involved in early onset colorectal cancer risk?

    by Mathilde Gay‐Bellile, Maud Privat, Alexandra Martins, Sandrine M. Caputo, Céline Pebrel‐Richard, Mathias Cavaillé, Sandrine Viala, Carole Corsini, Michael Rodrigues, Nicolas Barnich, et al.

    A, Closed symbols indicate patients affected with cancer. Open symbols indicate healthy individuals. The type of cancer and age at presentation are given in brackets. Blue circle represents c.4471_44...


  • Open Access

    BRACAVENIR: an observational study of expectations and coping in young women with high hereditary risk of breast and ovarian cancer

    by Fabrice Kwiatkowski, Mathilde Gay-Bellile, Pascal Dessenne, Claire Laquet, Véronique Boussion, Marie Béguinot, Marie-Françoise Petit, Anne-Sophie Grémeau, Céline Verlet, Charlotte Chaptal, et al.

    In families with high risk of hereditary breast/ovarian cancer (HBOC), women before age 30 do not yet undergo clinical screening, but they are exposed to contradictory information from diverse sources. They may be presented with surgical prevention options at a key moment of their identity construction, the start of a marital relationship and/or at the onset of procreation projects. We tested an original psychoeducational intervention to help these women better cope with these difficult issues. Seven young female counselees (26.4 ± 2.9 years [23–30]) from the Oncogenetics Department at Jean Perrin Comprehensive Cancer Center were enrolled. A weekend group workshop composed of short conferences, group sharing and role playing activities was supervised by a psychotherapist. A longitudinal analysis of questionnaires over one year of follow-up was performed. The Herth Hope Inventory was evaluated, as well as self-esteem, anxiety, perceived control, coping, and quality of life. Participants’ comments were collected by a genetic counselor throughout the workshop. All participants were BRCA mutation carriers and six had lived with a close relative affected by breast/ovarian cancer. Hope, self-esteem and quality of life increased during the year after the workshop (p = 0.0003). Coping by focus on the problem increased in the first 6 months (p = 0.011) and returned to baseline values at one year, while coping by focus on emotions decreased steadily (p = 0.021). Debriefing from the workshop highlighted the new medical opportunities proposed and the challenges these young women face, such as whether to have prophylactic surgery, and if so before or after having children, and how surgery might affect their relationship with their partner. A tailored two-day psychoeducational workshop may be sufficient to improve the way young women with BRCA mutations deal with the implications of HBOC risk. BRACAVENIR was registered in ClinicalTrials.gov with no NCT02705924.


  • Open Access

    Early Onset Multiple Primary Tumors in Atypical Presentation of Cowden Syndrome Identified by Whole-Exome-Sequencing

    by Mathias Cavaillé, Flora Ponelle-Chachuat, Nancy Uhrhammer, Sandrine Viala, Mathilde Gay-Bellile, Maud Privat, Yannick Bidet, Yves-Jean Bignon

    A family with an aggregation of rare early onset multiple primary tumors has been managed in our oncogenetics department: the proband developed four early onset carcinomas between ages 31 and 33 years, including acral melanoma, bilateral clear cell renal carcinoma (RC), and follicular variant of papillary thyroid carcinoma. The proband’s parent developed orbital lymphoma and small intestine mucosa-associated lymphoid tissue (MALT) lymphoma between 40 and 50 years old. Whole-exome-sequencing (WES) of the nuclear family (proband, parents, and sibling) identified in the proband a de novo deleterious heterozygous mutation c.1003C > T (p.Arg335∗) in the phosphatase and tensin homolog (PTEN) gene. Furthermore, WES allowed analysis of the nuclear family’s genetic background, and identified deleterious variants in two candidate modifier genes: CEACAM1 and MIB2. CEACAM1, a tumor suppressor gene, presents loss of expression in clear cell RC and is involved in proliferation of B cells. It could explain in part the phenotype of proband’s parent and the occurrence of clear cell RC in the proband. Deleterious mutations in the MIB2 gene are associated with melanoma invasion, and could explain the occurrence of melanoma in the proband. Cowden syndrome is a hereditary autosomal dominant disorder associated with increased risk of muco-cutaneous features, hamartomatous tumors, and cancer. This atypical presentation, including absence of muco-cutaneous lesions, four primary early onset tumors and bilateral clear cell RC, has not been described before. This encourages including the PTEN gene in panel testing in the context of early onset RC, whatever the histological subtype. Further studies are required to determine the implication of CEACAM1 and MIB2 in the severity of Cowden syndrome in our proband and occurrence of early onset MALT lymphoma in a parent.


  • Open Access

    TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer

    by Mathilde Gay-Bellile, Lauren Véronèse, Patricia Combes, Eleonore Eymard-Pierre, Fabrice Kwiatkowski, Marie-Mélanie Dauplat, Anne Cayre, Maud Privat, Catherine Abrial, Yves-Jean Bignon, et al.

    TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer


  • Open Access

    BRACAVENIR - impact of a psychoeducational intervention on expectations and coping in young women (aged 18–30 years) exposed to a high familial breast/ovarian cancer risk: study protocol for a randomized controlled trial

    by Fabrice Kwiatkowski, Pascal Dessenne, Claire Laquet, Jean-Pierre Daures, Mathilde Gay-Bellile, Yves-Jean Bignon

    Young women exposed to a high hereditary breast and ovarian cancer (HBOC) risk are particularly vulnerable. They are ignored by health prevention measures but exposed to a stream of contradictory information (medicine, media, Internet). They may feel concerned about surgical prevention issues at a key moment of their identity construction (self, relationship, sexuality). We designed a special psychoeducational intervention to help these women cope better with these difficulties. The BRACAVENIR study consists of a prospective, randomized superiority phase II trial with a wait list control group. Participants are childless young female counselees (aged 18–30 years) seen at the oncogenetics department of the Centre Jean Perrin and belonging to HBOC families either with or without BRCA mutations. They will be invited to attend a weekend group session at a spa resort and to participate in short expert conferences and focus group activities (group sharing, Moreno role game) supervised by a psychotherapist. Two sessions separated by a 6-month delay (wait list) will enable us to evaluate the intervention’s effect by comparing questionnaire scores between the 6-month time points. The main endpoint is an increase of the Herth Hope Index by at least 1 SD. Secondary endpoints are self-esteem, anxiety trait, anxiety state, coping, and quality of life. With a one-sided α = 0.05 and β = 0.20, 12 participants will be needed by group, plus an additional 2 in anticipation of dropouts. Participants will be randomized 1:1 to the first or the second session so that the groups will be comparable. The intent of this trial is to bridge the gap on a psychosocial level in these young women with HBOC. A particularity of the design is the use of a waiting list, which should allow for avoiding major bias. The intervention consists of a short session that could be proposed to other young counselees if successful. The results may bring complementary information to facilitate the intervention and also influence the contents of the oncogenetic consultation. Ethics committee CPP SUD-EST-6: IRB00008526. Registered on 18 March 2016. ClinicalTrials.gov identifier: NCT02705924 . Registered on 2 March 2016.